Annovis Bio (ANVS) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 17, 2025, to be held virtually for shareholders of record as of April 28, 2025.
Shareholders can access proxy materials online or request paper/email copies by June 10, 2025.
Voting is available online, by phone, or by email, with a deadline of June 16, 2025, at 11:59 PM ET.
Voting matters and shareholder proposals
Election of five director nominees: Michael Hoffman, Maria Maccecchini, Claudine Bruck, Reid McCarthy, and Mark White.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Board recommends voting "FOR" both proposals.
Other business may be transacted as properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Five director nominees are up for election at the annual meeting.
Latest events from Annovis Bio
- Buntanetap demonstrates cognitive and motor benefits in late-stage trials for AD and PD.ANVS
Corporate presentation26 Mar 2026 - Pivotal Phase 3 AD trial launched, OLE PD study underway, and cash runway extends into Q3 2026.ANVS
Q4 202516 Mar 2026 - Novel Alzheimer's drug shows strong cognitive gains and disease-modifying potential in trials.ANVS
H.C. Wainwright 27th Annual Global Investment Conference27 Dec 2025 - Shareholders will vote virtually on director elections and auditor ratification, with ESG and governance emphasized.ANVS
Proxy Filing2 Dec 2025 - Phase 3 Alzheimer's trial advances with strong enrollment and improved Q3 financials.ANVS
Q3 202513 Nov 2025 - Phase III Alzheimer's trial advances with strong early results; Parkinson's studies await funding.ANVS
Status Update12 Nov 2025 - Net loss and expenses declined, but more capital is needed for future clinical development.ANVS
Q3 202416 Oct 2025 - Phase 3 Alzheimer's trial progressed, net loss narrowed, and cash reserves increased.ANVS
Q2 202512 Aug 2025 - Strong clinical results and improved cash position, but long-term funding needs remain.ANVS
Q2 202413 Jun 2025